|1.||Yazdanparast, Razieh: 3 articles (10/2014 - 06/2011)|
|2.||Sharpe, Martyn A: 3 articles (03/2004 - 08/2002)|
|3.||Martin, Lee J: 2 articles (09/2012 - 01/2011)|
|4.||Ni, Xinli: 2 articles (09/2012 - 01/2011)|
|5.||Koehler, Raymond C: 2 articles (09/2012 - 01/2011)|
|6.||Carter, Erin L: 2 articles (09/2012 - 01/2011)|
|7.||Yang, Zeng-Jin: 2 articles (09/2012 - 01/2011)|
|8.||Budinger, G R Scott: 2 articles (05/2009 - 02/2004)|
|9.||Chandel, Navdeep S: 2 articles (05/2009 - 02/2004)|
|10.||Chatterjee, Prabal K: 2 articles (03/2004 - 09/2002)|
03/01/2004 - "Rats, subjected to bilateral renal ischemia (45 min) followed by reperfusion (6 h), were administered EUK-134 (0.3 and 3 mg/kg, i.v.) prior to and during reperfusion, after which biochemical and histological indicators of renal dysfunction and injury were measured. "
12/15/1996 - "Two hours after several periods of renal ischemia (30, 45, 60, and 75 min of left renal artery clamping), EUK-134 given at a similar dose significantly improved the glomerular filtration rate after an acute ischemia of 30 and 45 min, as assessed by EDTA 51Cr. "
01/01/2011 - "Striatal neuroprotection from neonatal hypoxia-ischemia in piglets by antioxidant treatment with EUK-134 or edaravone."
12/15/1996 - "Overall, these results show that synthetic superoxide dismutase-catalase mimetics such as EUK-134 can protect ischemically injured rat kidneys from ischemia-reperfusion syndrome when administered just before reperfusion."
12/15/1996 - "EUK-134, a synthetic superoxide dismutase and catalase mimetic, protects rat kidneys from ischemia-reperfusion-induced damage."
01/01/2012 - "In addition, EUK-8 and EUK-134 improved steatosis, ballooning degeneration and inflammation in liver of MCD-fed rats. "
05/01/2012 - "The ROS suppressors EUK-134 and α-lipoic acid, or small interfering RNA (siRNA)-mediated silencing of JNK expression, restored IGF1 sensitivity both in vitro and in vivo, and also ameliorated the impairment in IGF1-mediated wound responses during diabetes, inflammation and hypercortisolemia. "
05/16/2008 - "While EUK134, synthetic combined superoxide dismutase/catalase mimetic, had no effect on GO-mediated inflammation, sodium nitroprusside inhibited it. "
09/01/2012 - "Combining early EUK-134 treatment with delayed hypothermia also produced partial protection (47% ± 18%) that was not significantly greater than single treatment with EUK-134 (confidence interval of difference: -15% to 29%) or delayed hypothermia (-16% to 19%). "
09/01/2012 - "We conclude that early treatment with this antioxidant does not substantially enhance the therapeutic benefit of delayed hypothermia in protecting highly vulnerable neurons in HI-insulted newborns, possibly because basal ganglia neurons are already undergoing irreversible cell death signaling by the time EUK-134 is administered or because this compound and hypothermia attenuate similar mechanisms of injury."
09/01/2012 - "We tested the hypothesis that treatment with the superoxide dismutase-catalase mimetic EUK-134 at 30 minutes of recovery provides additive neuronal protection when combined with 1 day of whole-body hypothermia implemented 4 hours after resuscitation. "
04/01/2014 - "EUK-134 ameliorates nNOSμ translocation and skeletal muscle fiber atrophy during short-term mechanical unloading."
04/01/2014 - "EUK-134 mitigated the unloading-induced phenotype, including muscle fiber atrophy and muscle fiber-type shift from slow to fast. "
04/01/2014 - "We used EUK-134, a cell-permeable mimetic of superoxide dismutase and catalase, to test the role of redox signaling in nNOSμ translocation and muscle fiber atrophy as a result of short-term (54 h) hindlimb unloading. "
08/17/1999 - "Pretreatment of rats with EUK-134 did not modify the latency for or duration of KA-induced seizure activity. "
08/17/1999 - "The present study tested the effects of EUK-134, a synthetic superoxide dismutase/catalase mimetic, on several indices of oxidative stress and neuropathology produced in the rat limbic system as a result of seizure activity elicited by systemic kainic acid (KA) administration. "
|1.||N,N'- bis(salicylideneamino)ethane- manganese(II)
|2.||Edetic Acid (EDTA)
|5.||Potassium Channels (Potassium Channel)
|9.||Kainic Acid (Kainate)
|10.||Hydrogen Peroxide (Hydroperoxide)